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Abstract
Despite a high prevalence of oncogenic human papilloma virus (HPV) infection and cervical cancer mortality, HPV
vaccination is not currently available in Mali. Knowledge of HPV and cervical cancer in Mali, and thereby vaccine readiness,
may be limited. Research staff visited homes in a radial pattern from a central location to recruit adolescent females and
males aged 12–17 years and men and women aged $18 years (N= 51) in a peri-urban village of Bamako, Mali. Participants
took part in structured interviews assessing knowledge, attitudes, and practices related to HPV, cervical cancer, and HPV
vaccination. We found low levels of HPV and cervical cancer knowledge. While only 2.0% of respondents knew that HPV is
a sexually transmitted infection (STI), 100% said they would be willing to receive HPV vaccination and would like the HPV
vaccine to be available in Mali. Moreover, 74.5% said they would vaccinate their child(ren) against HPV. Men were found to
have significantly greater autonomy in the decision to vaccinate themselves than women and adolescents (p = 0.005),
a potential barrier to be addressed by immunization campaigns. HPV vaccination would be highly acceptable if the vaccine
became widely available in Bamako, Mali. This study demonstrates the need for a significant investment in health education
if truly informed consent is to be obtained for HPV vaccination. Potential HPV vaccination campaigns should provide more
information about HPV and the vaccine. Barriers to vaccination, including the significantly lower ability of the majority of the
target population to autonomously decide to get vaccinated, must also be addressed in future HPV vaccine campaigns.
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Introduction
Human papillomavirus (HPV) infection is a common and
necessary cause of cervical cancer [1]. Each year, 60 to 70% of all
cervical cancer cases worldwide are the result of high risk HPV
types 16 and 18, the oncogenic genotypes against which the
CervarixH and GardasilH vaccines protect [2–3]. Both vaccines
have been shown to be efficacious in preventing infection with
HPV types 16 and 18 among adolescent females and women [4–
6], however GardasilH is the only available vaccine efficacious
against HPV types 16 and 18 infection in males [7].
Eighty-percent of cervical cancer cases diagnosed each year
occur in developing countries [8], in part due to the lack of
availability of early prevention cytology-screening programs.
Educational and attitudinal barriers have also been identified as
major reasons for low screening prevalence in developing
countries [9–11]. In sub-Saharan Africa, cervical cancer rates
are among the highest in the world, with an age-standardized
incidence rate (ASR) of 31.0 per 100,000 women [12]. The HIV
epidemic is an important contributor to the cervical cancer burden
in sub-Saharan Africa [13]. HIV-seropositive women are six times
more likely to develop cervical cancer compared to HIV-
seronegative women due to HIV-related immune suppression
[14].
Other risk factors for HPV infection, and thereby the potential
for subsequent disease, include tobacco smoking, high parity, and
long-term hormonal contraceptive use [15]. Early age of first
sexual intercourse has long been associated with an increased risk
of cervical cancer, possibly due to the biological predisposition of
the immature cervix during adolescence with increased suscepti-
bility to persistent HPV infections and therefore a greater risk of
cervical cancer [16]. Age at first sexual intercourse, age at first
pregnancy, and age at first marriage are highly interrelated and
have similar cervical cancer risk estimates [17]. Moreover, the
influence of male partners, both directly and indirectly, on
women’s health has been demonstrated in the risk areas of
contraception, pregnancy, and childbirth [18].
Mali is a landlocked West African country with an estimated 13
million persons, 90% of whom are Muslim [19]. In Mali, high risk
HPV oncogenic types 16 and 18 have a prevalence of 12% among
previously unscreened women of the general population aged 15–
65 years [20–21], with predominant subtypes HPV-16 associated
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with 50% and HPV-18 associated with 12.7% of cervical cancer
[22]. Among Malian women, the ASR of cervical cancer is 37.7
cases per 100,000, the second highest rate of cervical cancer in the
sixteen West African countries [23]. Cervical cancer is not only the
most common cancer among women in Mali; it is also the leading
cause of all cancer-related mortalities among Malians [24].
However, only 4.8% of women (aged 18–69 years) have ever
been screened for cervical cancer in Mali and thus cervical cancer
rates may be higher than reported [23]. Due to a lack of cytology
screening and early treatment programs, the mortality rate among
Malian women diagnosed with cervical cancer is 80%, or 1,076
deaths per year [23].
HPV vaccination offers protection against the development of
cervical cancer and associated morbidities and mortalities, and is
especially valuable in resource-limited settings where secondary
prevention methods such as cytology screening are not widely
available and may not be a cost-effective [25]. Recent work
focusing on HPV vaccine acceptability in resource-limited settings
including Kenya, Tanzania, Uganda, Latin America, the Carib-
bean, Vietnam, Malaysia, China, and India have generally found
high acceptability of HPV vaccines [26–30]. Several studies have
shown that knowledge of HPV, cervical cancer, and risk factors for
cervical cancer are low among the general public, in both high and
low income settings [31–33]. At the time of this publication, only
one other study has quantitatively examined HPV vaccine
acceptability in West Africa, finding similar high levels of HPV
vaccine acceptability despite low levels of knowledge in Ghana
[34]. In the absence of accessible cytology screening, implementa-
tion of an HPV immunization program should be a public health
priority in Mali to reduce the high burden of cervical cancer-
associated morbidity and mortality. Moreover, Mali is eligible to
receive Global Alliance for Vaccines and Immunization (GAVI)
support for a two-year demonstration program in preparation for
national introduction of HPV vaccine. This support includes the
ability to purchase vaccines at a discounted price and grants to
build capacity for scaling up national immunization programs. A
mathematical modeling study assessing the impact of a single
vaccine campaign in Mali showed decreases in the prevalence of
HPV infection proportionate to achieved vaccination coverage
[20].
Sexually active adolescents and adults must voluntarily agree to
receive the vaccine, a decision affected by individual knowledge,
beliefs about susceptibility, perception of vaccine effectiveness,
family and physician perspectives, sexual and cultural practices,
and cost for vaccination [35]. This cross-sectional study aimed to
determine HPV knowledge, acceptability, and other factors
associated with the feasibility of HPV vaccine implementation in
Mali. To our knowledge, this is the first West African study to
include males and females aged 12 years and older in such an
assessment. We assessed adult and adolescent male and female
awareness and acceptance of HPV infection and vaccination for
cervical cancer prevention, as well as factors associated with
willingness to be administered the vaccine among individuals in
Me`kin-Sikoro, a peri-urban village in Bamako, Mali.
Methods
Ethics Statement
This research received ethical approval from the Committee of
Ethics of the Faculty of Medicine, Pharmacy, and Odonto-
Stomatology at the University of Bamako, Mali and the Ethical
and Independent Review Services West Coast Board, United
States.
Study Procedures
Face-to-face structured interviews were conducted in 2011 with
51 participants. All data collection activities took place prior to
HPV vaccine licensing in Mali. A two-stage sampling method was
utilized. Two geographical areas were selected from the peri-
urban village of Me`kin-Sikoro using a convenience sampling
technique according to their proximity to the central local health
clinic. In each of the selected sectors, interviewers approached
households starting with the nearest home to the central health
clinic.
Each interviewer was sex- and age-paired with a specific sample
subset; adolescent females, adolescent males, adult females, or
adult males. The interviewers approached households separately
such that one interviewer approached the closest household,
a second interviewer approached the next closest household,
a third interviewer approached the third closest household, and
a fourth interviewer approached the fourth nearest household.
Households were selected to participate if an eligible participant
was present at the time of visit. Adolescents were eligible if aged
12–18 years and living in the household, and a guardian was
available to provide consent. Adults were eligible if aged .18
years and living in the household. If a household had more than
one eligible inhabitant who could be sex- and age-matched with
the household interviewer, the first eligible individual to interact
with the interviewer was selected to undergo the informed consent
process after an explanation of the nature of the study. The
consent form was read aloud upon request and to all illiterate
individuals in Bambara, the main language in Mali [36]. Illiterate
individuals who chose to take part in the study completed the
informed consent process by signing with a fingerprint and
a literate witness verified the process with a signature.
A standardized questionnaire assessing knowledge, vaccine
acceptability and willingness to participate in an HPV vaccination
program, and demographic characteristics related to HPV and
cervical cancer was administered. Open response questions
included reasons why or why not most participants would
vaccinate themselves or their children, the preferred method for
contact about vaccination appointment, and the cost participants
would be willing to pay to receive HPV vaccination. The
structured interviews were conducted in Bambara.
Data was de-identified and analyzed using STATA 10.0 [37].
The significance level was set at p,0.05. Data analysis consisted of
descriptive statistics including frequencies and mean scores for the
demographic variables. Data are presented as mean (SD) for
continuous variables. Fischer’s exact tests were used to examine
differences found across participant subset responses.
Results
1. Characteristics of the Sample
A summary of the sample characteristics is provided in Table 1.
Of the total 52 eligible participants approached, 98.1% consented
to participation (n= 51). The mean age of participants was 26.1
years (SD614.58), with 49.0% of the participants adolescents aged
12–18 years. The majority of participants had received some
formal schooling (68.6%) and 69.2% of adults worked outside of
the home (58.3% females, 84.6% males). Of the 43.1% of
participants who were married, 36.4% were in polygamous
marriages with a mean of 2.25 wives (SD60.46). Among all
participants, the mean age of first marriage was 18.67 years
(SD64.03). The mean age of sexual debut was 17.0 years
(SD61.74) for females and males, and the mean number of total
sexual partners was reported to be 2.06 (SD61.87, females 1.40,
SD60.74; males 2.65, SD62.34). The majority of participants
HPV Vaccine Acceptability in Mali
PLOS ONE | www.plosone.org 2 February 2013 | Volume 8 | Issue 2 | e56402
reported being circumcised (80.8% males) or excised (Type 2
female genital cutting, 88.0% of females).
2. Knowledge of STIs, HPV and Cervical Cancer
Of the participants, 62.0% (68.0% females, 56.0% males)
reported they knew what an STI was, and 54.9% (64.0% females,
46.2% males) could correctly identify a method of protection
against STIs (Table 2). Just over half (54.9%) of participants knew
of places where STI screening and treatment were offered, and
23.5% of participants reported ever having an STI (40.0%
females, 7.7% males). Only one participant knew HPV was an
STI. Following a brief definition of HPV, 24.0% of participants
thought HPV only infects females only, 30.0% thought HPV only
infects males, 56.0% thought HPV infects both males and females,
and 14.0% did not know who was susceptible to HPV infection.
Only 9.8% of female participants had heard of cervical cancer.
3. Willingness to Vaccinate against HPV and
Immunization Preferences
Participant willingness to vaccinate and preferences for vacci-
nation are shown in Table 3. All participants had previously
received a vaccine, and 100% of participants said they would like
the HPV vaccine to be available in Mali. The majority of
participants would only receive immunization against HPV if the
vaccine were available at no cost to participant (68.6%). One-
hundred percent of participants reported being willing to receive
HPV vaccination, while only 74.5% were, or would be, willing to
vaccinate their child(ren) against HPV.
Participants suggested the following methods of contact for
receiving information about HPV vaccination appointments:
phone calls (41.2%), home visits (21.6%), messages at school
(17.7%), public crier (3.9%), text messaging (2.0%), and television
messages (2.0%). Participants preferred receiving the vaccine at
a local health clinic (46.0%), at a hospital (22.0%), at home
(22.0%), and at school (10.0%).
4. Autonomy in the Decision to Vaccinate
Ability to autonomously decide to vaccinate oneself against
HPV is summarized in Table 4, and was significantly different
across female adolescents (15.4%), male adolescents (46.2%), adult
female (75.0%) and adult male (76.9%) participants (Fishers exact
test p = 0.005). Adult males 76.9%) had 0.176 times the odds of
Table 1. Characteristics of study participants.
Characteristic Total Female Male
Mean (N) SD Mean (N) SD Mean (N) SD
Age: mean (SD) 26.1 (51) 14.6 24.4 (25) 10.9 27.7 (26) 17.5
Adolescents 14.1 (20) 1.6 13.8 (8) 1.5 14.3 (12) 1.8
Adults aged 18–26 years 20.2 (11) 2.6 20.4 (8) 3.0 19.7 (3) 1.5
Adults .26 years 41.4 (20) 11.6 37.4 (9) 4.8 44.6 (11) 14.5
Any school-based education 68.6% 64.0% 73.2%
Adult working outside the home (%) 69.2% (31) 58.3% (17) 84.6% (14)
Marital status (% married) 43.1% (51) 52.0% (25) 34.6% (26)
Adolescents 0.0% (20) 0.0% (8) 0.0% (12)
Adults 71.0% (31) 76.5% (17) 64.3% (14)
Polygamous marriage (%)1 36.4% (22) 30.8% (13) 44.4% (9)
Number of wives2 2.3 0.5 2.3 0.5 2.3 0.5
Age of first marriage 18.7 4.0 16.9 2.0 23.2 4.7
Age of sexual debut3 16.5 (22) 2.3 16.8 (15) 1.7 16.0 (7) 3.3
No sexual relations4 29.4% (15) 28.0% (7) 34.6% (8)
Refused to answer 27.5% (14) 1.2% (3) 42.3% (11)
.15 years (%) 40.9% 40.0% 42.9%
$15 and ,18 years (%) 36.4% 40.0% 28.6%
$18 years (%) 22.7% 20.0% 28.6%
Number of sexual partners5 2.1 (22) 1.9 1.4 (15) 0.7 2.7 (7) 2.3
Number of sexual partners before marriage6 1.0 (2.3) 0.4 0.7 1.9 3.2
Circumcised/excised7 84.3% 88.0% 80.8%
Refused to answer 7.8% 0.0% 15.4%
Sex in exchange for money or gifts 0.0% 41.7% 0.0%
Note. SD= standard deviation.
1Among those who were married (Number who were married).
2Among those reporting being in a polygamous marriage.
3Among those reporting having ever had sex (Number reporting ever having sex).
4Number reporting no sexual relations.
5Among those reporting having ever had sex (Number reporting ever having sex).
6Of those reporting marriage.
7Excision refers to Type II female genital cutting, or the removal of the clitoris and inner labia.
doi:10.1371/journal.pone.0056402.t001
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having the ability to vaccinate autonomously than females and
adolescent males (44.7%) (95%CI 0.03–0.61; McNemar’s test
p = 0.0026). Adult males had 10.0 times the odds of having the
ability to autonomously decide to vaccinate their child against
HPV (84.6%) compared to adult females and adolescents (64.5%)
(95%CI 2.43–88.24; McNemar’s test p = 0.0001).
Discussion
Our results are concordant with the existing literature on HPV
vaccine knowledge acceptability in both resource-rich and re-
source-limited settings, which is that while levels of knowledge are
generally low, individuals are willing to receive vaccination against
HPV [26–30] [38] [35]. We found that knowledge of HPV and
cervical cancer amongst participants was low, yet willingness to
receive HPV vaccination and willingness to vaccinate themselves
and/or their child was high. Our findings also suggest that relying
on cellular phones methods for modes of contact is not likely to
succeed in Mali, which in 2006 had low cell phone tower coverage
of 1.1% of area and 18.1% of population [39]. Moreover,
questions assessing preferences on the location for receiving
vaccine resulted in sample subset-specific responses; adolescents
were more likely to prefer vaccination at school and females to
prefer vaccination at home. The selection of sites at which to
distribute vaccine may need to be targeted to each eligible
subgroup. As the available HPV vaccine is recommended for use
in males and females aged 9–26 years, these differences will be
critical in developing immunization campaigns tailored to reach
both adult and adolescent males and females.
We identified that adult male participants were significantly less
likely to require permission from someone else in order to receive
the HPV vaccine in comparison to all other sample subsets. Adult
males also had higher odds of autonomy in the decision to
vaccinate their children than all other sample subsets. Our
research is, to the best of our knowledge, the first to study to
examine the differences in permission required to receive HPV
vaccination across all vaccine-eligible individuals. This informa-
tion is critical for the development of vaccine campaigns in settings
where all individuals do not have equal autonomy.
We identified men as the primary decision makers regarding
HPV vaccination, and as such they may be key targets for vaccine
campaigns. This attitude suggests that men are important factors
in the vaccination of women and adolescents, and better
immunization outcomes for women and adolescents may be
expected if men are involved in this population [18]. Frameworks
for a new reproductive health paradigm highlight the need to
incorporate men into emerging immunization programs [40–41].
Addressing men as actors in the health decisions of women and
children may be more important in the introduction of STI
vaccination in predominantly Muslim populations. In a study
conducted in Malaysia, a country where Islam is the national
Table 2. Understanding of STIs [Sexually Transmitted Infections], HPV, and cervical cancer.
Total % (N) Female % (N) Male % (N)
STIs
Knows what a sexually transmitted infection is 60.8% (51) 68.0% (25) 53.8% (26)
Adolescents 40.0% (20) 37.5% (8) 41.7% (12)
Adults 45.1% (51) 82.4% (17) 64.3% (14)
Knows how to protect against an STI 54.9% (51) 64.0% (25) 46.2% (26)
Adolescents 40.0% (20) 25.0% (8) 50.0% (12)
Adults 64.5% (31) 82.35% (17) 42.9% (14)
Knows where to get an STI exam8 96.6% (29) 100.0% (13) 93.3% (14)
Has had an STI 23.5% (51) 40.0% (25) 7.7% (26)
Refused 7.8% 8.0% 7.7%
Adolescents 80% (20) 75.0% (8) 83.3% (12)
Refused 20% 25.0% 16.7%
Adults 38.7% (31) 58.8% (17) 14.3% (14)
Refused 0.0% 0.0% 0.0%
HPV
Knows HPV is a sexually transmitted infection 2.0% (51) 0.0% (25) 3.8% (26)
Knows that HPV can affect:
Females only 24.0% 45.8% 3.8%
Males only 30.0% 0.0% 11.5%
Both females and males 56.0% 45.8% 65.4%
Don’t know 14.0% 8.3% 19.2%
Cervical cancer
Knows that HPV can cause cervical cancer 49.0% 44.0% 53.8%
Don’t know 39.2% 32.0% 46.2%
Knows that cervical cancer can cause death in women 0.0% 7.9% 0.0%
Note. HPV = human papillomavirus.
8Of those knowing what an STI was (Number knowing what an STI was).
doi:10.1371/journal.pone.0056402.t002
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religion, men were found to play an influential role in the
vaccination decisions of their children and spouses [38]. In this
study, men were in favor of protecting their spouses, partners, or
daughters from cervical cancer by HPV vaccination after receiving
information about HPV infection and vaccination [38]. In Mali,
adolescent females may marry as young as 15 years with parental
consent [42], and married adolescent females would require
permission from their husbands. Opt-out consent for HPV
vaccination was considered acceptable in Tanzania [29], and
represents a possible vaccination strategy addressing the lack of
autonomy female adolescents have in accessing health care.
Vaccinating adolescents before sexual debut was initially found
to be challenging in sub-Saharan Africa because of limited health
care funding, rare reproductive health services, and dispersed
populations [43], however more recent studies indicate that HPV
vaccination can be delivered with high coverage and acceptability
amongst adolescent females. Our findings on the age of sexual
debut are comparable to the results from previous research in
Bamako, Mali, finding that 40% of female adolescents and 25% of
male adolescents reported having had sex by the age of 15 years
[44]. Our study identifies autonomy in the decision to receive
vaccination as an additional barrier to the vaccination of women
and adolescents in Mali, West Africa. The association between
male circumcision and HPV transmission has been characterized;
however no studies have examined the relationship between
female circumcision and HPV infection in females. The great
Table 3. Willingness to participate in vaccination.
%
Ever received any vaccination 100.0%
Would like the HPV vaccine to be available in Mali 100.0%
Willing to receive HPV vaccine 100.0%
Willing to vaccinate child(ren) against HPV9 74.5%





Only if the vaccine were free 68.6%
Would prefer to be contacted to receive information about vaccination appointments by:
Phone call 41.2%
Text message 2.0%
A home visit 21.6%
Public crier 3.9%
Television 2.0%
A message at school 17.7%
Other 11.8%
Would prefer to receive the vaccine at:
A hospital 22.0%
The local health clinic 46.0%
School 10.0%
Home 22.0%
Note. HPV = human papillomavirus, USD=United States dollars.
9All participants were asked this question. This question was hypothetical for those without children.
10Percentages do not equal 100% due to rounding.
11Converted from CFA using an exchange rate of 539.4CFA/USD.
doi:10.1371/journal.pone.0056402.t003
Table 4. Autonomy in the decision to vaccinate.
Female adolescents Male adolescents Women Men Fisher exact test p-value
Would decide autonomously to receive HPV
vaccine:
15.4% 46.2% 75.0% 76.9% 0.005*
Would decide autonomously to vaccinate
child(ren):
33.3% 69.2% 75.0% 84.6% 0.185
Note. HPV = human papillomavirus.
*p-value,0.05.
doi:10.1371/journal.pone.0056402.t004
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majority of females in our study population were circumcised, and
thus the role of female circumcision in HPV prevalence requires
further investigation.
The sample size of this study is not representative, and thus
limitations of this research include the precision of the findings
which should be interpreted with caution. The unavailability of
data on the number of households and the population of each
household in Mekin-Sikoro and the convenience sampling of
households proximal to the health center are additional limitations
to this study. All interviews were conducted in the home, which
may have led to social desirability bias, particularly in response to
sexual history questions. Nevertheless, this study provides in-
formation to guide future representative studies of HPV knowl-
edge and vaccine acceptability in Mali, West Africa. The high rate
of willingness to receive HPV vaccination despite low HPV
knowledge presents ethical challenges to implementing an HPV
immunization program in Mali. Importantly, our results suggest
that autonomy in the decision to receive HPV vaccination is not
equally distributed in this setting and should be investigated. More
research is needed to further characterize decision makers and
incorporate this information into targeted HPV vaccine cam-
paigns.
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